Baselga J, Im SA, Iwata H, et al. PIK3CA status in circulating tumour DNA predicts efficacy of buparlisib plus fulvestrant in postmenopausal women with endocrine resistant HER+/HER2- advanced breast cancer: First results from the randomized, phase III BELLE-2 trial. San Antonio Breast Cancer Symposium. Abstract S6-01. Presented December 11,
Dickler MN, Tolaney SM, Rugo HS, et al. MONARCH 1: Results from a phase IIstudy of abemaciclib, a CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2- breast cancer, after chemotherapy for advanced disease. ASCO Annual Meeting. Abstract 510. Presented June 3, 2016..
Dirix LY, Takacs I, Nikolinakos P, et al. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: A phase Ib JAVELIN solid tumour trial. San Antonio Breast Cancer Symposium. Abstract S1-04. Presented December 9,
Rugo HS, Delord J-P. . Preliminary efficacy and safety of pembrolizumab (MK-3475) in patients with PDL1- positive estrogen receptor positive/HER2-negative advanced breast cancer enrolled in KEYNOTE-028. San Antonio Breast Cancer Symposium. Abstract S5-1 07. Presented December 11,
Reporting KN, Toxicity GF. J Clin Oncol 2014; 29: 3337-8.